Worldwide Is Invested in the Success of Your Myelofibrosis Study
Myelofibrosis is a myeloproliferative disease creating scar tissue in the bone marrow due to the bone marrow’s failure to generate healthy blood cells. As the condition rarely has any direct symptoms, detection is often difficult until other complications develop. Although symptoms may be hard to detect, the disease has a heavy impact on quality of life and carries a risk of developing into leukemia. Most myelofibrosis treatments aim to minimize the disease’s effects, since there are few known curative therapies. As new therapies are emerging to treat this disease, the challenge for drug developers is to achieve the necessary data in sufficient quantities in as timely a manner as possible.
An award-winning, full-service CRO with the agility of a midsized organization, Worldwide Clinical Trials brings together a long history of successful clinical trial design and execution with up-to-the-minute technology. Our global reach gives us access to remote patient populations and an understanding of local standards of care and regulatory considerations, enabling us to strategically select global sites. Using predictive analytics, we can identify patients who best meet inclusion/exclusion criteria, as well as those most likely to comply with protocol. You can have full confidence in our medical and scientific professionals’ ability to navigate the complexities of clinical trial design and execution.
When you need a CRO well-versed in Phase I-IV or real-world evidence studies, look no further than Worldwide Clinical Trials.